GlassScriptPhysician profile
John F Carmack
NPI 1639152812
$8,452.50
in general payments reported to CMS, 2019-2025
42 companies · $18.52 in 2025
The $18.52 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,328 · 2020: $1,392 · 2021: $1,663 · 2022: $1,289 · 2023: $1,853 · 2024: $909 · 2025: $18.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,405.30 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $849.04 | 2019-2024 | Farxiga, Bevespi Aerosphere |
| Janssen Pharmaceuticals, INC | $696.94 | 2019-2023 | Xarelto |
| Pfizer INC. | $631.82 | 2019-2024 | |
| Lilly USA, LLC | $560.84 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $558.24 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.60 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $447.70 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $322.73 | 2019-2024 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $230.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $226.60 | 2019-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Abbott Laboratories | $211.91 | 2019-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.36 | 2019-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $174.99 | 2019-2023 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $132.36 | 2020-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carmack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.